SBIR-STTR Award

Bedside Monitor to Quantify Cardiac Shunt Flow in Newborns and Small Children
Award last edited on: 4/11/16

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$450,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Nikolai M Krivitski

Company Information

Transonic Systems Inc (AKA: Transonic)

34 Dutch Mill Road
Ithaca, NY 14850
   (607) 257-5300
   info@transonic.com
   www.transonic.com
Location: Multiple
Congr. District: 23
County: Tompkins

Phase I

Contract Number: 1R43HL111852-01
Start Date: 8/23/11    Completed: 7/31/13
Phase I year
2011
Phase I Amount
$225,000
There is no current technology for routine measurement of shunt flow (Qp:Qs - ratio of pulmonary to systemic blood flow) in newborns and small children in the intensive care unit (ICU). Current methods either require placement of highly invasive catheter or depend on assumptions, leading to risky and less accurate measurement of shunt flow. Timely and accurate quantitative assessment of Qp/Qs permits successful pharmacologic, ventilator or fluid therapy or in time surgical intervention. Hence routine measurement of shunt flow is vital in the management of critically ill newborn and small children with cardiac defects. This SBIR grant will allow us to develop mathematical models and algorithms accounting for various shunts, clinical and physiological conditions. These will then be implemented into a monitor that could be used clinically at the bedside in a non-invasive manner with patients having in situ arterial and central venous catheters. The approach is based on well-established indicator dilution principles using innocuous isotonic saline as an indicator. These factors make the proposed monitor eminently suitable for used with neonatal and pediatric ICU patients. Main objectives of this proposal include - 1) Development of mathematical models and software algorithms for accurately quantifying shunt flow 2) Perform feasibility and validation testing of shunt flow measurements in animal models 3) Perform feasibility and clinical comparison of shunt flow measurements in newborns and small children. These objectives will be achieved in a concerted effort by Transonic's R&D staff, and its collaborators at University of Pittsburgh, PA and Crouse Hospital, NY. Successfully accomplishing Phase-I goals will test the feasibility of the proposed approach and guide further research to develop and clinically validate the first of its kind Bedside monitor for quantitative measurement of shunt flow in critically ill newborns and small children.

Public Health Relevance:
Accurate measurement of shunt flow (Qp:Qs - ratio of pulmonary to systemic blood flow) is vital for treating newborns and small children with congenital heart defects. Despite its clinical importance there currently exists no method that could be routinely used with this vulnerable patient population to accurately measure shut flow at the patient's bedside. Proposed monitor would allow neonatal and pediatric clinicians to routinely monitor shunt flow at the bedside for the first time. This would give them an opportunity to better manage the care of critically ill with cardiac shunts by providing accurate and timely assessment of Qp:Qs which could be used to assess the efficacy of therapy in real-time and thereby prevent related patient morbidity and mortality, and ultimately reduce short and long-term health care costs. The projected commercial success is based on the clear need in neonatal and pediatric ICUs for a simple, minimally invasive tool for quantitatively assessing shunt flow during the care of patients with congenital cardiac defects.

Thesaurus Terms:
0-11 Years Old;0-6 Weeks Old;Absence Of Interventricular Septum;Accounting;Affect;Algorithms;Animal Model;Animal Models And Related Studies;Animals;Aorta;Birth Defects;Blood Circulation;Blood Flow;Bloodstream;Cardiac;Cardiac Abnormalities;Cardiac Malformation;Cardiac Defect;Catheters;Child;Child Human;Child Youth;Childhood;Children (0-21);Circulation;Clinical;Common Ventricle;Computer Software;Congenital Abnormality;Congenital Anatomic Abnormality;Congenital Anatomical Abnormality;Congenital Cardiac Defects;Congenital Defects;Congenital Deformity;Congenital Heart Defects;Congenital Malformation;Cor Triloculare Biatriatum;Critical Care;Critical Illness;Critically Ill;Data;Development;Development And Research;Equilibrium;Feasibility Studies;Fluid Therapy;Goals;Grant;Health;Health Care Costs;Health Costs;Healthcare Costs;Heart;Heart Abnormalities;Heart Malformation;Hospital Charges;Hospitals;Irbs;In Situ;Institutional Review Boards;Intensive Care Units;Isokinetic Exercise;Isokinetics;Isotonic Exercise;Isotonics;Loinc Axis 4 System;Left;Length Of Stay;Lung;Lung Respiratory System;Managed Care;Math Models;Measurement;Measures;Methods;Modeling;Molecular Genetic Abnormality;Monitor;Morbidity;Morbidity - Disease Rate;Mortality;Mortality Vital Statistics;Neonatal;Newborn Infant;Newborns;Number Of Days In Hospital;O Element;O2 Element;Operative Procedures;Operative Surgical Procedures;Oxygen;Patient Care;Patient Care Delivery;Patients;Pediatric Intensive Care Units;Phase;Physiologic;Physiological;Physiology;Pulmonary Artery;Pulmonary Artery Structure;R &D;R&D;Research;Sbir;Sbirs (R43/44);Saline;Saline Solution;Shapes;Shunt;Shunt Device;Small Business Innovation Research;Small Business Innovation Research Grant;Software;Surgical;Surgical Interventions;Surgical Procedure;System;Techniques;Technology;Testing;Time;Treatment Efficacy;Universities;Validation;Venous;Ventilator;Balance;Balance Function;Base;Blood Flow Measurement;Body Fluid Balance Therapy;Cardiopulmonary System;Children;Computer Program/Software;Critically Ill Newborn;Death In First Year Of Life;Develop Software;Developing Computer Software;Developmental;Effective Therapy;Effective Treatment;Heart Defect;Hemodynamics;Hospital Days;Hospital Length Of Stay;Hospital Stay;Improved;In Vivo;Infant Death;Infant Demise;Infantile Death;Intervention Efficacy;Mathematical Algorithm;Mathematical Model;Mathematical Modeling;Meetings;Minimally Invasive;Model Organism;Newborn Human (0-6 Weeks);Patient Population;Pediatric;Prevent;Preventing;Pulmonary;Research And Development;Sensor;Shunts;Single Functional Ventricle;Single Ventricle;Software Development;Success;Surgery;Therapeutic Efficacy;Therapeutically Effective;Therapy Efficacy;Tool;Univentricular Heart;Youngster

Phase II

Contract Number: 5R43HL111852-02
Start Date: 8/23/11    Completed: 7/31/15
Phase II year
2012
Phase II Amount
$225,000
There is no current technology for routine measurement of shunt flow (Qp:Qs - ratio of pulmonary to systemic blood flow) in newborns and small children in the intensive care unit (ICU). Current methods either require placement of highly invasive catheter or depend on assumptions, leading to risky and less accurate measurement of shunt flow. Timely and accurate quantitative assessment of Qp/Qs permits successful pharmacologic, ventilator or fluid therapy or in time surgical intervention. Hence routine measurement of shunt flow is vital in the management of critically ill newborn and small children with cardiac defects. This SBIR grant will allow us to develop mathematical models and algorithms accounting for various shunts, clinical and physiological conditions. These will then be implemented into a monitor that could be used clinically at the bedside in a non-invasive manner with patients having in situ arterial and central venous catheters. The approach is based on well-established indicator dilution principles using innocuous isotonic saline as an indicator. These factors make the proposed monitor eminently suitable for used with neonatal and pediatric ICU patients. Main objectives of this proposal include - 1) Development of mathematical models and software algorithms for accurately quantifying shunt flow 2) Perform feasibility and validation testing of shunt flow measurements in animal models 3) Perform feasibility and clinical comparison of shunt flow measurements in newborns and small children. These objectives will be achieved in a concerted effort by Transonic's R&D staff, and its collaborators at University of Pittsburgh, PA and Crouse Hospital, NY. Successfully accomplishing Phase-I goals will test the feasibility of the proposed approach and guide further research to develop and clinically validate the first of its kind Bedside monitor for quantitative measurement of shunt flow in critically ill newborns and small children.